News Column

Data on Enzyme Inhibitors Reported by Researchers at Medical University (The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic...

August 22, 2014



Data on Enzyme Inhibitors Reported by Researchers at Medical University (The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon)

By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Biotechnology have been presented. According to news reporting originating in Lubeck, Germany, by NewsRx journalists, research stated, "Potent and safe inhibitors of norovirus replication are needed for the treatment and prophylaxis of norovirus infections. We here report that the in vitro anti-norovirus activity of the protease inhibitor rupintrivir is extended to murine noroviruses and that rupintrivir clears human cells from their Norwalk replicon after only two passages of antiviral pressure."

The news reporters obtained a quote from the research from Medical University, "In addition, we demonstrate that rupintrivir inhibits the human norovirus (genogroup II [GII]) protease and further explain the inhibitory effect of the molecule by means of molecular modeling on the basis of the crystal structure of the Norwalk virus protease. The combination of rupintrivir with the RNA-dependent RNA polymerase inhibitors 2'-C-methylcytidine and favipiravir (T-705) resulted in a merely additive antiviral effect. The fact that rupintrivir is active against noroviruses belonging to genogroup I (Norwalk virus), genogroup V (murine norovirus), and the recombinant 3C-like protease of a GII norovirus suggests that the drug exerts cross-genotypic anti-norovirus activity and will thus most likely be effective against the clinically relevant human norovirus strains."

According to the news reporters, the research concluded: "The design of antiviral molecules targeting the norovirus protease could be a valuable approach for the treatment and/or prophylaxis of norovirus infections."

For more information on this research see: The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon. Antimicrobial Agents and Chemotherapy, 2014;58(8):4675-4681. Antimicrobial Agents and Chemotherapy can be contacted at: Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA. (American Society for Microbiology - www.asm.org; Antimicrobial Agents and Chemotherapy - aac.asm.org)

Our news correspondents report that additional information may be obtained by contacting J. Rocha-Pereira, Medical University of Lubeck, German Center Infect Res DZIF, D-23538 Lubeck, Germany. Additional authors for this research include M.S.J. Nascimento, Q. Ma, R. Hilgenfeld, J. Neyts and D. Jochmans (see also Biotechnology).

Keywords for this news article include: Antiretrovirals, Antivirals, Biotechnology, Drugs, Lubeck, Europe, Germany, Therapy, Viral RNA, Enzyme Inhibitors, Protease Inhibitors, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters